Audience
HCP Other (Non-Derm) panel (US)
HCP Other (Non-Derm) (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.
What did the HCP Other (Non-Derm) panel say?
- #
37.1%
37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. — Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
base 70
- #
22.9%
22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. — New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
base 70
What has Brox published on hcp other (non-derm) panel (us)?Newest first
-
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read
What do people ask about hcp other (non-derm) panel (us)?
- How much does a patient's out-of-pocket cost change what a physician is willing to prescribe?
- Between $25 and $75 a month: 4.3% of US physicians and other prescribers outside dermatology would pick a $5 generic over the brand-name medicine they prefer when the brand costs the patient $25 a month, 44.3% at $75 and 62.9% at $150 (n=70, November 2026).Read the insight
- What makes a physician try a newly launched medicine in its first six months: the trial data, a peer, the rep, or coverage?
- Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).Read the insight
Other audiences
- Anime Fans (US) 4
- Brox HNWI (US) 8
- Casual dining and restaurants (US) 2
- E-commerce (US) 7
- Finance (US) 5
- G.B. nat. rep. (GB) 14
- GLP-1 (US) 1
- GLP-1 Considerers (US) 2
- GLP-1 Past Users (US) 3
- Groceries (US) 3
- HCP (US) 10
- HCP Dermatologists (US) 4
- Healthcare (US) 10
- Healthcare Professionals (US) 1
- HNWI (VC/Tech) (US) 3
- Insurance (US) 15
- Investing (US) 1
- Japan nat. rep. (JP) 1
- Music (US) 1
- Streaming (JP) 1
- Streaming (US) 16
- Streaming (TR) 1
- Streaming - Custom (US) 2
- Tech (US) 5
- Tech (GB) 1
- Travel (US) 6
- TV & Social Media (JP) 1
- U.S. nat. rep. (US) 102
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai